Pharmaceutical and Medical Devices Agency (PMDA) review process
Under PMD Act, the Pharmaceutical and Medical Devices Agency (PMDA) review process depends on the classification of the medical device, which is generally in line with the principles outlined by the International Medical Device Regulators Forum:
Class I General Medical Devices: Pre-Market Submission (Todokede)
- Devices of low risk to the human body
- Approval of the product is not required, but marketing notification (Todokede) to PMDA is necessary
Class II and Class III (partially) Controlled Medical Devices: Pre-Market Certification (Ninsho)
- Low risk to the human body
- The majority of these devices for which certification standards have been established by MHLW, are eligible for third-party review and certification by a Registered Certification Body, such as BSI. Those devices for which no applicable certification standard has been established must be submitted to PMDA for approval (Shonin) by MHLW
Class III and IV Specially Controlled Medical Devices: Pre-Market Approval (Shonin)
- Medium risk to human body, high risk to human body, highly invasive to patients
- MHLW approval (shonin) is required for Class III and IV devices, based on approval standards for devices for which such standards have been established, or based on review guidelines
Japan and the Medical Device Single Audit Program (MDSAP)
The Medical Device Single Audit Program (MDSAP) allows manufacturers to undergo a single audit to meet the QMS/GMP requirements of multiple Regulatory Authorities (RAs). The Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceutical and Medical Devices Agency (PMDA) are participating RAs, after joining the pilot phase of the Program in June 2015. The MHLW and PMDA will utilize MDSAP audit reports in both pre-market and periodical post-market audit under regulations in Japan. MDSAP audits are conducted by recognized Auditing Organizations (AOs); BSI is a recognized AO and participated in the Program's pilot phase. Find out more about the Program, who is involved and BSI's role now.
What is BSI's role in market access in Japan?
We are one of four Registered Certification Bodies (RCB) that is authorized to conduct certifications by the MHLW for all types of Class II Designate Controlled Medical Devices and In-Vitro Diagnostic Reagents. We also provide a number of solutions for our global customers wishing to access the Japanese market. So as your company grows and expands sales into overseas markets, we can help you meet the increasingly complex regulatory schemes and certifications.
Streamlined audits can help save you money
We have auditors qualified to conduct MO 169 audits in Asia, Europe and the Americas, and can combine the required PMD Act audits with our clients’ ISO 13485 and Notified Body audits, streamlining the process. And to help save you from additional audits, our reports covering ISO 13485 and MO 169 are accepted by other RCBs for use in conjunction with their reviews of product submissions from their Market Authorization Holder (MAHs).
Helping smaller companies overcome global challenges
Newly established or smaller companies may have a challenge obtaining a Japan-based Market Authorization Holder (MAH) with QMS & GVP capability to hold the marketing approval. Japan has harmonized the QMS requirements with ISO 13485, but there are additional requirements that will fall under the responsibility of overseas manufacturers under Ministerial Ordinances’ requirements for accreditation. With experience working with companies of all sizes, we can help you break into this highly regulated yet profitable overseas market.
Our core competencies and unique skills are calibrated to handle our customer’s extensive portfolio of medical technologies which include: